Baxter International, Inc. (NYSE:BAX)

12/13

9/6/2011 BNY port rotate out of OXY to BAX 8/17/2011 at 53.51 can buy today at 52.48

SUCCESS

Covestor Model Manager SWAN-asset management sold BAX in his Christian Agape Hedged Equity Covestor Model ( http://covestor.com/SWAN-asset-management )

Buying new companies

It is another beneficiary of the healthcare and is a low cost provider of hospital IV products that are essential. They are very active in discovering a man made blood replacement for emergency uses, and if ever they make the discovery , it will go to the moon, right!

I think this is a classic value play (and has a 2.5% dividend to boot). BAX has shown solid earnings growth and FCF, has a history repurchasing shares, and is, in my opinion, temporaily depressed due to a macro slowdown in protein plasma and antibody therapy. This presents a great buying opportunity.

This stock will eventually turn out in good shape from its recall on infusion pumps, but for now it should return to the 40 dollar per share range

taking a beating from the bad news in europe but it will rebound by years end.

Baxter was a shining star for me until April.... I'm going to pick some up in real life now that its dropped down to 40.... Does the market realize this is a Medical Technology conglomerate? And I know they cited the new Health Care Reform as an excuse as to why their revenues will be lower, but I don't get this. If EVERYONE get's insurance now, how does that negatively impact a medical technology supplier? Further, with Health Information Technology being one of the components of the required changes to healthcare, why not jump on that? Maybe the problem is management? Any thoughts? Any reason not to start nibbling at $40 a share?

-one time charge for teva related propofol negligible in the macro view
-continue dominance as hospital supplier
-also good as safe harbor to park money with dividend yield

Financials are strong, company is well diversified, located in over 55 countries and on every continent. Good investment.

Company has addressed setbacks and stock will preform well over the next 12 months

I work for Baxter - Could be in for a run, after the recent restating of projected earning and an approx. 15% drop in share price. Some of the updates/expansions to current high selling products should be just about ready for market by Q3 or 4.

After a big then deserved hit, think this company will outpreform market over next several months.

Investors overreacted to management's caution projections. The basics of the financials appear sound and in line with the industry. However, I do not undersatand how they arrive at a 0.58 debt to equity ratio.

copying translator's pick. interested to follow this along

Solid healthcare company being oversold on a recent near-term report as well as healthcare bill effects. Starting to average into this issue for the long haul.

BAX has an attractive mix of products, but I think the most attractive, and most overlooked segment is the Renal business. BAX is the only major health care company that produces products for peritoneal dialysis (PD), which is non-blood-based dialysis used at home. The other two major players in the renal market - Fresenius and Gambro (which product Baxter distributes) produces products for hemodialysis (HD), a blood-based therapy conducted in a clinic or hospital.

In the US, >80% end-stage kidney disease (ESRD) patients are on HD, which is generally more expensive and more inconvenient. This trend is changing as more people adopt PD as an acceptable treatment. For example, in the UK, Hong Kong, South Korea and Mexico, PD is the predominant form of treatment, with >70% of patients on PD and <30% on HD. The fact that Baxter is focused on PD means that the company will be a beneficiary to this trend. The global ESRD product market is ~US$10 billion and Baxter has ~20% market share. This can easily grow to 30-40% if the move from HD to PD materialize, especially if the health care reform push physicians to recommend the cheaper PD as the standard treatment.

The ESRD market itself is also growing. The grow of ESRD patient base is due aging of the global population coupled with longer lifespans, higher rate of related diseases such as diabetes or hypertension as a result of increasing affluence of the population and lower mortality rates. In particular, More than 200 million people worldwide are diabetic and this is expected to rise to almost 400 million by 2025. ~40% of diabetics will develop chronic kidney disease.